Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease by Mattsson, N et al.
Research Article
Cerebrospinal fluid tau, neurogranin, and
neurofilament light in Alzheimer’s disease
Niklas Mattsson1,2,*, Philip S Insel1,3, Sebastian Palmqvist1,2, Erik Portelius4, Henrik Zetterberg4,5,
Michael Weiner3, Kaj Blennow4, Oskar Hansson1,2,**, for the Alzheimer’s Disease Neuroimaging Initiative†
Abstract
Cerebrospinal fluid (CSF) tau (total tau, T-tau), neurofilament light
(NFL), and neurogranin (Ng) are potential biomarkers for neurode-
generation in Alzheimer’s disease (AD). It is unknown whether
these biomarkers provide similar or complementary information in
AD. We examined 93 patients with AD, 187 patients with mild
cognitive impairment, and 109 controls. T-tau, Ng, and NFL were
all predictors of AD diagnosis. Combinations improved the diagnos-
tic accuracy (AUC 85.5% for T-tau, Ng, and NFL) compared to
individual biomarkers (T-tau 80.8%; Ng 71.4%; NFL 77.7%). T-tau
and Ng were highly correlated (q = 0.79, P < 0.001) and strongly
associated with b-amyloid (Ab) pathology, and with longitudinal
deterioration in cognition and brain structure, primarily in people
with Ab pathology. NFL on the other hand was not associated with
Ab pathology and was associated with cognitive decline and brain
atrophy independent of Ab. T-tau, Ng, and NFL provide partly inde-
pendent information about neuronal injury and may be combined
to improve the diagnostic accuracy for AD. T-tau and Ng reflect
Ab-dependent neurodegeneration, while NFL reflects neurodegen-
eration independently of Ab pathology.
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Introduction
Alzheimer’s disease (AD) is a progressive disease characterized
by accumulation of amyloid b (Ab) and tau pathologies,
neurodegeneration, and cognitive and functional decline. Bio-
markers, including cerebrospinal fluid (CSF) measurements, may
quantify AD-related brain changes in vivo, which has revolutionized
research, clinical trial design, and clinical practice (Mattsson et al,
2015a). CSF total tau (T-tau) is a well-studied biomarker, which is
increased in neuronal degeneration (Blennow et al, 2006) and in AD
patients already in early clinical stages (Mattsson et al, 2009; Albert
et al, 2011; McKhann et al, 2011; Sperling et al, 2011; Dubois et al,
2014). CSF neurogranin (Ng) and neurofilament light (NFL) are two
other biomarkers that have recently been suggested to measure
neurodegeneration in AD. Ng is a post-synaptic protein (Gerendasy
& Sutcliffe, 1997) and a putative marker of synaptic loss in AD
(Portelius et al, 2015), an event which may be closely linked to
development of cognitive decline (Portelius et al, 2015). CSF Ng is
increased in AD compared to other dementias (Janelidze et al, 2016;
Wellington et al, 2016), already in early clinical stages (Kvartsberg
et al, 2015; Tarawneh et al, 2016). CSF Ng is also associated with
brain atrophy (Portelius et al, 2015; Tarawneh et al, 2016) and
reduced brain glucose uptake (Portelius et al, 2015). NFL is a puta-
tive marker of subcortical large-caliber axonal degeneration, and
increased CSF NFL has been linked to inflammatory diseases
(Christensen et al, 2013) and frontotemporal lobe dementia (Petzold
et al, 2007). But CSF NFL is also relevant in AD (Zetterberg et al,
2016) since AD not only involves loss of cortical structures but also
white matter injury (Migliaccio et al, 2012) and disconnection of
cortical and subcortical regions (Delbeuck et al, 2003).
It is unknown whether T-tau, Ng, and NFL provide independent
information about AD and whether measuring Ng or NFL in addi-
tion to T-tau improves the diagnostic accuracy for AD. The aim of
this study was therefore to compare T-tau, Ng, and NFL for AD
diagnosis and test their associations with other AD hallmarks.
Specifically, we tested the hypotheses that (i) combinations of
T-tau, Ng, and NFL increase the diagnostic accuracy for AD versus
controls (CN) and for progressive mild cognitive impairment
(PMCI) versus stable MCI (SMCI); (ii) T-tau, Ng, and NFL have
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different associations with Ab pathology and with different clinical
stages of AD; and (iii) T-tau, Ng, and NFL have different associa-
tions with other AD features, including cognitive decline, brain
atrophy, brain hypometabolism, and white matter hyperintensities
(WMH).
Results
The study included 93 patients with AD, 187 patients with MCI, and
109 controls (Table 1). For some analyses, we contrasted PMCI
(N = 104) versus SMCI (N = 65, Table 2).
Demographics
T-tau and Ng were higher in females than in males (T-tau: median
90 ng/l versus 80 ng/l, P = 0.036; Ng: 467 ng/l versus 374 ng/l,
P = 0.0024), while NFL was higher in males (7.22 versus 7.04 [log]
ng/l, P < 0.001). T-tau and Ng were higher in APOE e4+ than in
APOE e4 participants (T-tau: 103 ng/l versus 69 ng/l, P < 0.001;
Ng: 491 ng/l versus 343 ng/l, P < 0.001), while NFL did not differ
by APOE e4 status (7.16 versus 7.09 [log] ng/l, P = 0.15). NFL was
higher (q = 0.32, P < 0.001) and Ng was lower (q = 0.13,
P = 0.013) in older people, while T-tau (q = 0.0092, P = 0.86) did
not vary with age. Likewise, NFL was higher (q = 0.10, P = 0.040)
and Ng was lower (q = 0.13, P = 0.0089) in people with higher
education, while T-tau had no correlation with education
(q = 0.072, P = 0.16).
Correlations between CSF T-tau, Ng, and NFL
T-tau, Ng, and NFL were all correlated (Fig 1A–C), and the correla-
tion between T-tau and Ng was especially strong. T-tau, Ng, and
NFL correlated negatively with Ab42 (Fig 1D–F).
Diagnostic accuracy of CSF T-tau, Ng, and NFL
We tested accuracies for AD dementia versus CN and for PMCI
versus SMCI using logistic regression models (Table 3). T-tau,
Ng, and NFL were all significant predictors of AD. For single
predictors, T-tau had the highest accuracy, followed by NFL and
Ng. The model with the highest accuracy used all biomarkers
together (AUC 85.5%). For PMCI versus SMCI, T-tau and Ng, but
not NFL, were significant individual predictors. No combination
had higher AUC than the model using only T-tau. We also evalu-
ated models adjusted for demographics (age, sex, and education)
and demographics plus Ab42 (Table EV1). These models had
higher AUCs than the basic models without covariates, but the
overall results and relationship between the different models
were similar.
We noted that there was a special relationship between T-tau
and Ng, so that when Ng was adjusted for T-tau, the effect of Ng on
AD diagnosis often changed from positive to negative (for example,
from b = 0.85 to b = 0.56, Table 1). When adjusting for other
covariates, this inversed effect of Ng was statistically significant,
indicating that low Ng was associated with AD when the models
were adjusted for T-tau (Table EV1).
Biomarker combinations for classification of
patients and controls
We extracted classification tables from the logistic regression
models generated above, based on a threshold of 50% for the
predicted probability of the logistic regression models. The results
are summarized in Table 4. T-tau correctly classified 59 of 93 AD
and 90 of 109 CN. Adding Ng improved the classification of CN to
93 of 109, without changing the classification of AD. In contrast,
adding NFL improved the classification of AD to 61 of 93 but wors-
ened the classification of CN to 87 of 109. Adding both Ng and NFL
improved the classification of both AD (66 of 93, a relative increase
of 12% from 59 of 93) and only slighly affected the classification of
CN (89 of 109 CN). When also adjusting for age, sex, and Ab42,
NFL had the highest correct classification rate (correctly classifying
79 of 93 AD and 93 of 109 CN), and there was no improvement
when combining biomarkers. For PMCI versus SMCI, all models had
high correct classification of PMCI and poor classification of SMCI.
Adjusting for age, sex, and Ab42 greatly improved classification of
SMCI.
CSF T-tau, Ng, and NFL across clinical diagnoses and
Ab pathology
For the next set of analyses, participants were grouped based on the
combination of clinical diagnosis and Ab pathology (CN Ab,
Table 1. Demographics.
CN MCI AD P-value
N 109 187 93 NA
Age (years) 75.7 (5.2) 74.5 (7.5) 74.7 (8.0) 0.33
Sex (F/M, % F) 54/55 (50%) 62/125 (33%) 41/52 (44%) 0.015
APOE e4
(+/, % +)
26/83 (24%) 100/87 (54%) 65/28 (70%) 0.001
Education
(years)
15.8 (2.9) 15.8 (3.0) 15.1 (3.2) 0.25
Continuous data are mean (standard deviation). P-values tested by Fisher’s
exact and Kruskal–Wallis test. CN, healthy controls; MCI, mild cognitive
impairment; AD, Alzheimer’s disease dementia.
Table 2. MCI demographics.
SMCI PMCI P-value
N 65 104 NA
Age 73. 9 (7.4) 74.5 (7.6) 0.44
Sex (F/M, % F) 21/44 (32%) 37/67 (36%) 0.74
APOE e4 (+/, % +) 28/37 (43%) 63/41 (61%) 0.039
Education (years) 16.0 (3.0) 15.9 (3.0) 0.52
Clinical follow-up
(years)
4.5 (2.4) 4.4 (2.5) 0.22
Continuous data are mean (standard deviation). Note that the total number
differs from the complete MCI cohort. For the SMCI versus PMCI comparisons
we only included SMCI subjects with at least 2 years of follow-up. P-values
tested by Fisher’s exact test and Mann–Whitney U-test. SMCI, stable mild
cognitive impairment; PMCI, progressive mild cognitive impairment.
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N = 69; CN Ab+, N = 40; MCI Ab, N = 50; MCI Ab+, N = 137;
AD Ab, N = 8; AD Ab+, N = 85). We performed different comparisons
of CSF biomarkers between these groups. All models were adjusted
for age and sex.
We first compared CSF biomarkers between Ab-positive and
Ab-negative people within diagnosis (Fig 2 and upper part of
Table 5). Ab positivity was associated with increased T-tau in all
diagnostic groups and with increased Ng in MCI, but never with NFL.
We next compared CSF biomarkers between CN Ab and all
other combinations of diagnosis and Ab pathology. These compar-
isons were based on the theory that AD progresses from CN Ab to
CN Ab+, MCI Ab+, and finally AD Ab+, while non-Ab-dependent
A B C
D E F
Figure 1. Biomarker correlations.
A–F Associations between CSF T-tau, Ng, and NFL (panels A–C) and between these biomarkers and CSF Ab42 (panels D–F). Black circles: CN (n = 109), red triangles: MCI
(n = 187), blue crosses: AD (n = 93). Associations are shown for Spearman correlations. Ab42 and T-tau were measured using the INNOBIA AlzBio3 kit (Fujirebio,
Ghent, Belgium), Ng was measured using an in-house immunoassay for Ng (Portelius et al, 2015) and NFL was measured using the NF-light® ELISA kit (Uman
Diagnostics, Umeå, Sweden).
EMBO Molecular Medicine Vol 8 | No 10 | 2016 ª 2016 The Authors
EMBO Molecular Medicine CSF tau, neurogranin, and NFL in AD Niklas Mattsson et al
1186
Published online: August 17, 2016 
cognitive decline may progress from CN Ab to MCI Ab and AD
Ab (we consider these AD Ab cases to be clinically misdiag-
nosed). Compared to CN Ab, T-tau was increased in CN Ab+, MCI
Ab+, and AD Ab+, while Ng was increased in MCI Ab+ and AD
Ab+. In contrast, NFL was increased in all groups with cognitive
decline (MCI Ab+, AD Ab+, MCI Ab, and AD Ab).
Finally, we compared the strengths of the associations
between CSF biomarkers with different combinations of diagnosis
Table 3. Diagnostic accuracy of CSF biomarkers.
Groups Model T-tau Ng NFL AUC (95% CI) AIC
AD versus
CN
T-tau only 1.61 (< 0.001) 80.8 (74.3–86.4) 216.3
Ng only 0.85 (< 0.001) 71.4a (64.1–77.9) 254.7
NFL only 1.38 (< 0.001) 77.7 (71.4–83.8) 228.9
T-tau & Ng 2.11 (< 0.001) 0.56 (0.074) 81.4b (75.2–87.3) 215.0
T-tau & NFL 1.33 (< 0.001) 0.98 (< 0.001) 84.9a,b,c (79.8–89.8) 198.1
Ng & NFL 0.61 (0.0016) 1.19 (< 0.001) 80.6b,c,e (74.7–86.2) 219.7
T-tau & Ng & NFL 1.80 (< 0.001) 0.52 (0.11) 0.99 (< 0.001) 85.5a–f (80.6–90.6) 197.4
PMCI versus
SMCI
T-tau only 0.56 (0.0035) 67.7 (58.6–75.2) 219.2
Ng only 0.39 (0.027) 60.4a (50.6–68.8) 223.9
NFL only 0.32 (0.069) 58.9 (48.8–68.0) 225.6
T-tau & Ng 0.60 (0.038) 0.046 (0.86) 68.2b (58.4–76.2) 221.2
T-tau & NFL 0.52 (0.0082) 0.20 (0.23) 67.5b,c (58.1–76.0) 219.7
Ng & NFL 0.38 (0.29) 0.30 (0.076) 63.0 (54.2–72.3) 222.5
T-tau & Ng & NFL 0.49 (0.10) 0.028 (0.92) 0.21 (0.23) 67.3b,c (59.0–76.5) 221.7
A separate logistic regression model was fit for each combination of neurodegeneration biomarkers in AD dementia versus CN and in PMCI versus SMCI. The
table includes coefficients (log odds) with P-values, AUC, and AIC. For AUC, the letters a-f indicate significant differences (P < 0.05, tested by bootstrap) versus
other models: T-tau (a), Ng (b), NFL (c), T-tau & Ng (d), T-tau & NFL (e), Ng & NFL (f). Bold values indicate significant associations. AD, Alzheimer’s disease
dementia; AIC, Akaike information criterion; AUC; area under the receiver operating characteristic curve; CN, healthy controls; PMCI, progressive mild cognitive
impairment; SMCI, stable mild cognitive impairment.
Table 4. Classification tables.
Biomarkers
AD versus CN PMCI versus SMCI
Correct
overall, %
Correct
AD
Correct
CN
Correct
overall, %
Correct
PMCI
Correct
SMCI
No covariates
T-tau only 73.8 59/93 90/109 68.0 95/104 20/65
Ng only 66.3 46/93 88/109 63.9 98/104 10/65
NFL only 72.3 60/93 86/109 64.5 102/104 7/65
T-tau & Ng 75.2 59/93 93/109 68.6 96/104 20/65
T-tau & NFL 73.3 61/93 87/109 69.8 96/104 22/65
Ng & NFL 70.8 59/93 84/109 65.1 95/104 15/65
T-tau & Ng & NFL 76.7 66/93 89/109 69.8 96/104 22/65
Adjusted for age, sex, education, and Ab42
T-tau only 81.7 73/93 92/109 72.7 90/104 33/65
Ng only 75.7 72/93 81/109 71.6 90/104 31/65
NFL only 85.1 79/93 93/109 73.4 93/104 31/65
T-tau & Ng 80.7 74/93 89/109 72.8 90/104 33/65
T-tau & NFL 84.7 78/93 93/109 73.4 93/104 31/65
Ng & NFL 84.7 79/93 92/109 71.0 89/104 31/65
T-tau & Ng & NFL 84.7 78/93 93/109 72.1 91/104 31/65
Classification tables from logistic regression models using a threshold of 50% for predicted probabilities. AD, Alzheimer’s disease dementia; CN, healthy controls;
PMCI, progressive mild cognitive impairment; SMCI, stable mild cognitive impairment.
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and Ab pathology. When comparing them head-to-head, T-tau
and Ng had similar strengths of associations with all groups
(shown in Table 5 as non-significant differences for T-tau and
Ng). The only exception was that T-tau was more strongly asso-
ciated with AD Ab+ (i.e., the difference between CN Ab and
AD Ab+ was larger for T-tau than for Ng; b = 0.312, P = 0.045).
NFL differed markedly from T-tau and Ng and was more strongly
associated with MCI Ab and AD Ab than T-tau and Ng were
(Fig 2 and Table 5).
Associations with cognition, MRI, and FDG-PET measures
Finally, we tested associations between biomarkers and cognition,
brain structure, brain metabolism, and WMH. Baseline data are
A B C
Figure 2. Biomarkers by diagnosis and amyloid pathology.
A–C CSF T-tau (panel A), Ng (panel B) and NFL (panel C) in different combinations of clinical diagnosis and Ab pathology (CN Ab, n = 69; CN Ab+, n = 40; MCI Ab,
n = 50; MCI Ab+, n = 137; AD Ab, n = 8; AD Ab+, n = 85) (see Table 5 for comparisons between groups). Biomarker levels are standardized to z-scores and shown
in box plots (indicating median and interquartile ranges; whiskers are defined as quartiles 1 and 3  1.5 × interquartile range, respectively). Ab42 and T-tau were
measured using the INNOBIA AlzBio3 kit (Fujirebio, Ghent, Belgium), Ng was measured using an in-house immunoassay for Ng (Portelius et al, 2015), and NFL was
measured using the NF-light® ELISA kit (Uman Diagnostics, Umeå, Sweden). Ab was defined as CSF Ab42 < 192 ng/l.
Table 5. Associations between biomarkers, clinical diagnosis and amyloid pathology.
Comparison CSF T-tau CSF Ng CSF NFL
Difference
T-tau versus Ng
Difference
T-tau versus NFL
Difference
Ng versus NFL
Associations between neurodegeneration biomarkers and Ab pathology within diagnostic group
CN Ab versus CN Ab+ 0.528 (0.0069) 0.332 (0.087) 0.102 (0.60) 0.197 (0.32) 0.426 (0.031) 0.229 (0.24)
MCI Ab versus MCI Ab+ 0.824 (< 0.001) 0.727 (< 0.001) 0.00778 (0.96) 0.0970 (0.61) 0.816 (< 0.001) 0.719 (0.00015)
AD Ab versus AD Ab+ 0.789 (0.040) 0.618 (0.11) 0.632 (0.098) 0.171 (0.67) 1.420 (0.00057) 1.249 (0.0024)
Associations between neurodegeneration biomarkers and combinations of clinical diagnosis and Ab pathology
CN Ab versus CN Ab+ 0.528 (0.0069) 0.332 (0.087) 0.102 (0.60) 0.197 (0.32) 0.426 (0.031) 0.229 (0.24)
CN Ab versus MCI Ab+ 0.916 (< 0.001) 0.816 (< 0.001) 0.798 (< 0.001) 0.100 (0.52) 0.119 (0.45) 0.0185 (0.91)
CN Ab versus AD Ab+ 1.172 (< 0.001) 0.860 (< 0.001) 0.973 (< 0.001) 0.312 (0.045) 0.199 (0.20) 0.113 (0.47)
CN Ab versus MCI Ab 0.119 (0.51) 0.120 (0.51) 0.633 (0.00067) 0.00141 (0.99) 0.514 (0.014) 0.513 (0.015)
CN Ab versus AD Ab 0.494 (0.18) 0.0564 (0.88) 1.40 (0.00028) 0.438 (0.24) 0.909 (0.016) 1.35 (0.00040)
Results for comparisons between different combinations of clinical diagnosis and Ab pathology (CN Ab, n = 69; CN Ab+, n = 40; MCI Ab, n = 50; MCI Ab+,
n = 137; AD Ab, n = 8; AD Ab+, n = 85) from linear mixed-effects models testing effects of Ab within diagnostic groups (top 3 rows), and differences between
Ab CN and other combinations of Ab and diagnosis (bottom 5 rows). The data correspond to Fig 2. Results are b-coefficient (P-value). For example, in the top row
(“CN Ab versus CN Ab+”), the effect of T-tau indicates that CN Ab+ was significantly associated with 0.528 standard deviations higher levels of T-tau. The
columns marked “difference” test whether the comparison differed between two biomarkers. For example, in the top row (“CN Ab versus CN Ab+”), the
difference for T-tau versus NFL indicates that CN Ab+ was significantly more associated with T-tau than with NFL. Bold values indicate significant associations.
CN, healthy controls; MCI, mild cognitive impairment; AD, Alzheimer’s disease dementia.
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shown in Fig 3, and longitudinal data are shown in Fig 4. The
models were adjusted for age, sex, and education (for cognitive
measures) and intracranial volume (for MRI measures).
At baseline, high T-tau was associated with poor cognition in
Ab. A detailed analysis suggested that this association was driven
by the AD Ab individuals (i.e. subjects with a clinical diagnosis of
AD but without evidence of Ab pathology, not shown). T-tau was
surprisingly associated with smaller ventricular volumes in both
Ab and Ab+. Over time, high T-tau was associated with worsening
cognition (MMSE in Ab and Ab+, ADAS-cog in Ab+), hippocampal
atrophy, and hypometabolism (in Ab+). Ng was associated
with smaller baseline ventricles in both Ab and Ab+, with
worsening cognition, hippocampal atrophy, and hypometabolism
over time in Ab+, and with slightly slower expansion of ventricle
volume in Ab.
To explore the unexpected associations between high T-tau and
Ng and small baseline ventricles, we performed post hoc analyses
within diagnostic subgroups (using ordinary linear regression,
adjusted for intracranial volume, age, and sex). We found signifi-
cant associations between high T-tau and small baseline ventricles
in CN Ab (b = 0.25, P = 0.016) and MCI Ab+ (b = 0.18,
P = 0.0064) and between high Ng and small baseline ventricles in
MCI Ab (b = 0.39, P = 0.0020) and MCI Ab+ (b = 0.26,
P = 0.0012). Even in groups where the associations were not signifi-
cant, the highest T-tau and Ng levels were constantly seen in
subjects with small baseline ventricles, and subjects with large base-
line ventricles had low T-tau and Ng (Figs EV1 and EV2).
NFL had markedly different patterns of association compared to
T-tau and Ng. At baseline, high NFL was associated with worse
cognition, smaller hippocampal volumes, larger ventricles and
lower FDG-PET in both Ab and Ab+ people (the effects were stron-
gest in Ab). Over time, NFL was associated with worsening cogni-
tion (Ab and Ab+), acceleration of hippocampal atrophy (Ab),
and expansion of ventricles (Ab and Ab+).
Discussion
We compared CSF T-tau, NFL, and Ng, which are all putative
biomarkers for neurodegeneration in AD. The main findings were
that (i) combining biomarkers improved the diagnostic accuracy for
AD versus CN compared to using individual biomarkers; (ii) T-tau
and Ng were highly correlated and associated with Ab pathology
across clinical stages of AD, while NFL correlated with cognitive
decline independent of Ab pathology; and (iii) T-tau and Ng were
associated with acceleration of cognitive decline, atrophy, and hypo-
metabolism primarily in the presence of Ab pathology, while NFL
was associated with decline independent of Ab pathology. In sum,
our results support that CSF T-tau and Ng reflect neurodegeneration
in AD, while NFL reflects neurodegeneration independent of AD.
Combinations of these biomarkers provide partly complimentary
information about diagnosis and pathology in people with cognitive
decline.
The first main finding was that all biomarkers identified AD
versus controls, and combinations improved the diagnostic accuracy
compared to using individual biomarkers. The triple combination of
T-tau, Ng, and NFL had the highest AUC, but the increase was small
compared to the combination of T-tau and NFL. However, although
combinations of biomarkers significantly increased the accuracy
measured by AUC, the biomarker combinations tested here only
had modest effects on the proportion of correctly classified people,
especially when also adjusting the models for demographics and
CSF Ab42. For PMCI versus SMCI, T-tau and Ng, but not NFL, were
significant predictors and no combination was significantly better
than T-tau alone. We expected the biomarkers to be less accurate in
MCI than in AD dementia, since some SMCI subjects may have
non-AD diseases (e.g., vascular disease or non-AD tauopathies)
reducing the specificity of the biomarkers.
The fact that NFL had high accuracy for AD is in line with several
studies showing increased CSF levels of neurofilaments in AD
Figure 3. Baseline associations between CSF T-tau, Ng, and NFL and other AD traits.
A–F Data are estimates (b-coefficients) from linear mixed-effects models, with 95% confidence intervals. The estimates are the main effects of the biomarkers,
capturing the effects at study baseline. Effects were significant (*) for MMSE (A): T-tau (P = 0.034) and NFL (P < 0.0001) in Ab for ADAS-cog (B): NFL in Ab
(P = 0.0013) and Ab+ (P = 0.024); for hippocampal volume (C): NFL in Ab (P < 0.0001); for lateral ventricles (D): T-tau (P = 0.0019), Ng (P = 0.00092), and NFL
(P = 0.0024) in Ab and T-tau (P = 0.00083) and Ng (P < 0.0001) in Ab+ and for FDG-PET (E): NFL in Ab (P = 0.046) and Ab+ (P = 0.0041) people. Biomarkers
and outcomes were standardized to z-scores. Note that the y-axes for ADAS-cog, ventricle size, and WMH are flipped, so that the lower ranges constantly
reflect “worse” outcomes. Note also that the range of the y-axes differs for the different outcomes, for visualization purposes. Models were adjusted for age and
sex, and education (for cognitive measures), and intracranial volume (for MRI measures). Ab42 and T-tau were measured using the INNOBIA AlzBio3 kit
(Fujirebio, Ghent, Belgium), Ng was measured using an in-house immunoassay for Ng (Portelius et al, 2015), and NFL was measured using the NF-light® ELISA
kit (Uman Diagnostics, Umeå, Sweden).
Figure 4. Longitudinal associations between CSF T-tau, Ng, and NFL and other AD traits.
A–F Data are estimates (b-coefficients) from linear mixed-effects models, with 95% confidence intervals. The estimates are the effect of time plus the biomarker by
time interactions, capturing the longitudinal effects of the biomarkers. For each model, the “average” effect of time is also shown for comparison. Effects were
significant (*), meaning that biomarker levels affected the slopes of the outcome, for MMSE (A): T-tau (P = 0.021) and NFL (P < 0.0001) in Ab and for T-tau
(P < 0.0001), Ng (P = 0.0031) and NFL (P < 0.0001) in Ab+ for ADAS-cog (B): NFL in Ab (P < 0.0001) and for T-tau (P < 0.0001), Ng (P = 0.0015) and NFL
(P = 0.0027) in Ab+ for hippocampal volume (C): NFL in Ab (P = 0.0048) and for T-tau (P = 0.0015) and Ng (P = 0.0027) in Ab+ for lateral ventricles (D): Ng
(P = 0.0051) and NFL (P < 0.0001) in Ab and NFL (P < 0.0001) in Ab+; and for FDG-PET (E): T-tau (P = 0.00038) and Ng (P = 0.0019) in Ab+ people. Biomarkers
and outcomes were standardized to z-scores. Note that the y-axes for ADAS-cog, ventricle size, and WMH are flipped, so that the lower ranges constantly
reflect “worse” outcomes. Note also that the range of the y-axes differs for the different outcomes, for visualization purposes. Models were adjusted for age and
sex, and education (for cognitive measures), and intracranial volume (for MRI measures). Ab42 and T-tau were measured using the INNOBIA AlzBio3 kit
(Fujirebio, Ghent, Belgium), Ng was measured using an in-house immunoassay for Ng (Portelius et al, 2015), and NFL was measured using the NF-light® ELISA
kit (Uman Diagnostics, Umeå, Sweden).
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(Rosengren et al, 1999; Sjo¨gren et al, 2001; Hu et al, 2002;
Zetterberg et al, 2016). However, NFL is also increased in other
neurological conditions, including inflammatory diseases (Mattsson
et al, 2010; Christensen et al, 2013), Creutzfeldt-Jakob disease (van
Eijk et al, 2010), acute neuronal ischemia (Merisson et al, 2016),
subcortical vascular dementia (Skillba¨ck et al, 2014), atypical
parkinsonian disorders (Hall et al, 2012), and frontotemporal lobe
dementia (FTD) (Petzold et al, 2007; Pijnenburg et al, 2007;
Landqvist Waldo et al, 2013) where levels correlate with disease
severity (Scherling et al, 2014). More work is needed to scrutinize
CSF NFL in biomarker algorithms for differential diagnostics (de
Jong et al, 2007).
The next main finding was that T-tau and Ng were strongly
associated with Ab pathology and more advanced clinical stages of
AD. Specifically, T-tau and Ng were associated with Ab pathology
within diagnostic groups and with increased levels in CN Ab+,
MCI Ab+, and AD Ab+ compared to CN Ab. This links T-tau
and Ng to Ab-pathology and shows that this association is
present at all clinical stages of AD, including the prodromal and
preclinical stages (Dubois et al, 2016), which is in line with other
recent reports on Ng in other cohorts (Hellwig et al, 2015;
Tarawneh et al, 2016). In contrast, NFL was not associated with
Ab-pathology within diagnostic groups and was increased also in
MCI Ab and AD Ab participants compared to CN Ab. This
shows that CSF NFL is a non-specific marker of injury, which is
not primarily related to AD. This is consistent with previous
reports on increased CSF NFL in different neurological conditions,
as explained above.
The next finding was that the biomarkers had different relation-
ships with different outcomes. T-tau and Ng primarily had
associations with deterioration in the presence of Ab pathology,
which was seen in longitudinal analyses of cognition, hippocampal
atrophy, and hypometabolism. In contrast, NFL had associations
with cognition, ventricular expansion, and hypometabolism in both
Ab and Ab+ people and with longitudinal hippocampal atrophy
only in Ab people. Taken together, these results are compatible
with a model where non-Ab and non-tau pathologies (which may
include vascular pathology, TDP-43, Lewy bodies and other patholo-
gies) are associated with high NFL levels, expansion of ventricles,
and some degree of hippocampal atrophy at baseline, but the
progressive hippocampal volume loss seen in people harboring Ab
pathology is independent of NFL and is instead reflected by
increased CSF levels of T-tau and Ng.
Unexpectedly, we found negative associations between T-tau
and Ng and ventricle size at baseline. One possible interpretation of
this is that T-tau and Ng not only reflect neuronal injury, but may
also be related to normal neuronal function or transmission, hypo-
thetically resulting in a relationship between high biomarker levels
and small ventricle volume. Another unexpected finding was that
when we combined T-tau and Ng in one model for AD diagnosis,
the sign for Ng (but not T-tau) was reversed compared to when it
was used alone (Table 3). This indicates that when Ng is used
alone to predict AD, high levels are associated with disease, but
when it is adjusted for T-tau, low levels are associated with disease.
This finding fits with our speculation that Ng partly reflects normal
neuronal function. More in-depth studies are needed to clarify
mechanisms affecting CSF Ng levels in contrast to CSF T-tau. One
recent study found that Ng increases over time in cognitively
normal people (Kester et al, 2015). The reason for this is unknown,
but further longitudinal studies will be important to clarify the role
of these biomarkers.
Several recent studies on Ng in AD have been published by us
and other groups (Portelius et al, 2015; Tarawneh et al, 2016;
Wellington et al, 2016). Compared to these, our study is novel by
simultaneously investigating CSF T-tau, Ng, and NFL and by test-
ing whether these biomarkers provide independent information
about AD diagnosis and brain changes associated with AD in
several different clinical stages of the disease. However, our study
is not without limitations. We did not include non-AD neurode-
generative diseases, and we did not include neuropathology data.
For the comparison between PMCI and SMCI, we only included
SMCI subjects who were stable for at least 2 years to reduce the
number of subjects erroneously classified as stable. However, it is
possible that some SMCI subjects would have progressed to AD
dementia with longer follow-up. A final limitation is that we used
a fixed cut-point of CSF Ab42 (192 ng/l) to test the effects of
brain Ab pathology, although it is possible that there may be
subtle effects of emerging Ab pathology in subjects with slightly
higher CSF Ab42 levels (Mattsson et al, 2014, 2015b; Insel et al,
2015, 2016).
T-tau, NFL, and Ng contribute independent information in char-
acterization of CN, MCI, and AD. Combinations of these biomark-
ers, particularly T-tau and NFL, may increase the diagnostic
accuracy of AD. T-tau and Ng are closely associated with Ab
pathology at all clinical stages of AD. The independent roles of Ng
and T-tau need further clarification. In contrast to T-tau and Ng,
NFL reflects neurodegeneration that is not associated with Ab
pathology. Future studies may explore whether CSF T-tau, Ng, and
NFL respond differently to successful disease-modifying treatment
against AD.
Materials and Methods
ADNI study design
Data were obtained from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database (adni.loni.usc.edu). The principal investi-
gator of this initiative is Michael W. Weiner, MD, VA Medical Center
and University of California, San Francisco. ADNI subjects have
been recruited from over 50 sites across the USA and Canada (for
up-to-date information, see http://www.adni-info.org). Regional
ethical committees of all institutions approved of the study. All
subjects provided informed consent.
ADNI subjects
We included all CN, MCI, and AD dementia subjects with available
T-tau, NFL, and Ng data. Inclusion/exclusion criteria are described
at http://www.adni-info.org. Briefly, all subjects included were
between the ages of 55 and 90 years, had completed at least
6 years of education, were fluent in Spanish or English, and were
free of any significant neurological disease other than AD. CN had
Mini Mental State Examination (MMSE) score ≥ 24 and Clinical
Dementia Rating (CDR) score 0. MCI had MMSE score ≥ 24, objec-
tive memory loss as shown on scores on delayed recall of the
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Wechsler Memory Scale Logical Memory II (> 1 standard devia-
tions below the normal mean), CDR 0.5, preserved activities of
daily living, and absence of dementia. AD dementia patients ful-
filled the National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and Related
Disorders Association (NINCDS-ADRDA) criteria for probable AD
(McKhann et al, 1984) and had MMSE 20–26 and CDR 0.5–1.0. For
some analyses, we contrasted PMCI versus SMCI. We defined PMCI
as MCI subjects converting to AD dementia anytime during follow-
up and SMCI as MCI subjects not converting to AD dementia
during at least 2 year of follow-up.
CSF measurements
CSF procedures have been described previously (Shaw et al, 2009).
Ab42, T-tau, and P-tau were measured at the ADNI biomarker core
(University of Pennsylvania) using the multiplex xMAP Luminex
platform (Luminex Corp, Austin, TX, USA) with the INNOBIA
AlzBio3 kit (Fujirebio, Ghent, Belgium). Ng and NFL were measured
at the Clinical Neurochemistry Laboratory at University of Gothen-
burg, Mo¨lndal, Sweden, using an in-house immunoassay for Ng
(Portelius et al, 2015) and a commercial ELISA for NFL (NF-light
ELISA, Uman Diagnostics, Umea˚, Sweden) (Zetterberg et al, 2016).
We excluded two subjects who were significant outliers in Ng
measurements (CSF Ng > 2,000 ng/l).
Cognition
Cognition was assessed by MMSE and ADAS-Cog11 up to 13 times:
baseline and at 6, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, and
120 months after baseline.
Brain structure
Structural magnetic resonance imaging brain scans were acquired
using 1.5 Tesla MRI scanners up to nine times: baseline and at 6,
12, 18, 24, 36, 48, 60, and 72 months. We used a standardized
protocol including T1-weighted MRI scans using a sagittal volumet-
ric magnetization prepared rapid gradient echo (MP-RAGE)
sequence (Jack et al, 2008). Automated volume measures were
performed with FreeSurfer. We used averaged volume measure-
ments for the right and left hippocampi and combined volumes for
the lateral ventricles.
Brain metabolism
FDG-PET image data were acquired up to 11 times (baseline and at
6, 12, 18, 24, 36, 48, 60, 72, 84, and 96 months after baseline)
(Landau et al, 2012). We used mean FDG-PET counts of the lateral
and medial frontal, anterior, and posterior cingulate, lateral parietal,
and lateral temporal regions.
White matter hyperintensities
White matter hyperintensities (WMH) were quantified up to
seven times (baseline and at 6, 12, 18, 24, 36, and 48 months
after baseline) using a fully automated protocol (Schwarz et al,
2009).
Statistical analysis
Nonparametric tests (Kruskal–Wallis, Mann–Whitney U, and Spear-
man correlation) were used to test associations between biomarkers
and demographic factors. The main analyses consisted of 4 different
parts:
1 Diagnostic accuracies were tested in logistic regression
models separately for AD versus CN and PMCI versus SMCI.
All models were evaluated for significance of the included
biomarkers, overall diagnostic accuracy (area under the
receiver operator characteristics curve, AUC), and overall fit
penalized for the number of predictors (Akaike information
criterion, AIC). Differences between AUCs were calculated in
a bootstrap procedure with resampling (B = 1,000
iterations). We also tested models adjusted for age, sex,
education, and CSF Ab42. We extracted classification tables
from the logistic regression models to quantify correct classi-
fications of AD, CN, PMCI, and SMCI, using a 50% threshold
of predicted probability.
2 We next tested the effects of Ab on biomarkers within diagnos-
tic groups. We dichotomized each diagnostic group using a
previously established cutoff of CSF Ab42 (< 192 ng/l; Shaw
et al, 2009) and compared Ab versus Ab+. CSF biomarkers
were standardized and concatenated into a single response
vector, which was used as the dependent variable in linear
mixed-effects models. The independent variable was an inter-
action between Ab and a factor for biomarker type, adjusted
for both main effects, age, and sex. All models included a
random intercept. The interaction between Ab and biomarker
type is an estimate of the different effect of Ab in two different
CSF biomarkers.
3 We next tested the combination of diagnostic group and Ab
status as predictor (“group”). We hypothesized that AD
progresses from CN Ab to CN Ab+, MCI Ab+, and AD Ab+.
In this paradigm, MCI Ab and AD Ab represent non-AD
causes of cognitive decline (we consider the AD Ab cases
likely to be clinically misdiagnosed). We again used linear
mixed-effects model with concatenated CSF biomarker levels
as the response, and an interaction between “group” and a
factor for biomarker type as predictor (with CN Ab as the
reference group), adjusted for age and sex.
4 Finally, we tested CSF biomarkers as predictors of different AD
features, including MMSE, ADAS-cog, hippocampal volume,
ventricular volume, FDG-PET, and WMH. This was done with
longitudinal response data, using linear mixed-effects models.
The predictors were a biomarker by time (years) interaction,
age, sex, diagnosis (CN, MCI, and AD), and all main effects.
Cognition was also adjusted for education and volume
measures for intracranial volume. The models included
random intercepts and slopes and an unstructured covariance
matrix for the random effects. Models were tested separately
for Ab and Ab+ people.
NFL was used after logarithmic transformation. All continuous
variables were standardized (scaled and centered). b-coefficients
from regressions refer to standardized effects (b = 1 indicates that a
1 standard deviation increase in the tested biomarker was associated
with a 1 standard deviation increase in the dependent variable). We
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checked model assumptions by inspecting residuals (correlations
with fitted values and predictors of interest, histograms and q–q
plots). All tests were two sided. Significance was determined at
P < 0.05. All statistics were done using R (v. 3.2.3, The R Founda-
tion for Statistical Computing).
Expanded View for this article is available online.
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